These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32738042)

  • 1. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
    Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
    Lee PA; Luce M; Bacher P
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
    Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P
    Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Pre-injection Basal Luteinizing Hormone Concentrations are Common in Girls Treated for Central Precocious Puberty.
    Schubert S; Hvelplund AH; Handberg A; Hagstroem S; Leunbach TL
    J Clin Res Pediatr Endocrinol; 2021 Jun; 13(2):204-211. PubMed ID: 33374097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unstimulated Luteinizing Hormone for Assessment of Suppression during Treatment of Central Precocious Puberty with 6-Month Subcutaneous Leuprolide Acetate: Correlations with Clinical Response.
    Klein KO; Miller BS; Mauras N
    Horm Res Paediatr; 2024 Apr; ():1-10. PubMed ID: 38684152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y; Wei H; Zhang JL; Hou L; Luo XP
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty.
    Fuld K; Chi C; Neely EK
    J Pediatr; 2011 Dec; 159(6):982-7.e1. PubMed ID: 21798557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR; Aceto T; Weber C; Pang S
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
    Kunz GJ; Sherman TI; Klein KO
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate.
    Klein KO; Dragnic S; Soliman AM; Bacher P
    J Pediatr Endocrinol Metab; 2018 Jun; 31(6):655-663. PubMed ID: 29750651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
    Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
    J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).
    Carel JC; Lahlou N; Jaramillo O; Montauban V; Teinturier C; Colle M; Lucas C; Chaussain JL
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4111-6. PubMed ID: 12213857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty.
    Badaru A; Wilson DM; Bachrach LK; Fechner P; Gandrud LM; Durham E; Wintergerst K; Chi C; Klein KO; Neely EK
    J Clin Endocrinol Metab; 2006 May; 91(5):1862-7. PubMed ID: 16449344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.